1256359-09-7 Usage
Uses
Used in Medicinal Chemistry:
1H-Indazole, 1-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)is used as a building block for the synthesis of pharmaceutical compounds, leveraging its reactivity and the ability to form stable intermediates in various chemical reactions. The presence of the dioxaborolane group facilitates cross-coupling reactions, which are crucial for the development of new drugs with specific therapeutic properties.
Used in Materials Science:
In the field of materials science, 1H-Indazole, 1-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)is used as a precursor for the development of novel materials with unique electronic, optical, or mechanical properties. The indazole ring and the boron-containing group can be further functionalized to create materials with tailored characteristics for specific applications.
Used in Organic Synthesis:
1H-Indazole, 1-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)serves as a versatile reagent in organic synthesis, particularly for the preparation of complex organic molecules. The dioxaborolane group acts as a protecting group for alcohols and amines, allowing for selective reactions and the synthesis of target compounds with high yields and purity.
Check Digit Verification of cas no
The CAS Registry Mumber 1256359-09-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,5,6,3,5 and 9 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1256359-09:
(9*1)+(8*2)+(7*5)+(6*6)+(5*3)+(4*5)+(3*9)+(2*0)+(1*9)=167
167 % 10 = 7
So 1256359-09-7 is a valid CAS Registry Number.
1256359-09-7Relevant academic research and scientific papers
4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF
-
Page/Page column 192; 193, (2017/01/09)
The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., lung cancer, breast cancer, leukemia, lymphoma, melanoma, multiple myeloma, Ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase (e.g. a protein kinase (e.g. a cyclin-dependent kinase (CDK) (e.g. CDK7, CDK12, or CDK13) or a lipid kinase such as a phosphatidylinositol- 5 -phosphate 4- kinase (PIP4K) (e.g., ΡΙ5Ρ4Κα, ΡΙ5Ρ4Κβ, or ΡΙ5Ρ4Κγ)) in the subject.
SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS
-
Page/Page column 46, (2014/06/24)
The present invention relates to pyridopyrazine compounds of formula (I), pharmaceutical compositions thereof and methods of use therefore, wherein R1, R2, R3, L, m, p and W are as defined in the specification.
